{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-24-000035","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.312433+00:00","generated_at":"2026-06-02T00:17:05.323358+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Curis expands TakeAim Leukemia study to 30 patients; 6/11 FLT3m and 4/18 SFm respond","bullets":["TakeAim Leukemia dataset expanded from 5 to 30 R/R AML patients (25 new) with emavusertib monotherapy at 300 mg BID.","FLT3m cohort: 6/11 evaluable patients achieved objective response (3 CR, 1 CRh, 2 MLFS); responses mostly in one cycle.","SFm cohort: 4/18 evaluable patients achieved objective response (1 CR, 2 CRh, 1 MLFS); 3 additional patients showed increased neutrophils.","All responders had complete bone marrow blast normalization; two patients proceeded to allogenic stem cell transplant.","Curis discloses insufficient cash to fund operations for next 12 months, highlighting need for additional capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-24-000035","json":"https://secwatch.observer/filing/0001108205-24-000035.json","markdown":"https://secwatch.observer/filing/0001108205-24-000035.md","text":"https://secwatch.observer/filing/0001108205-24-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000035/0001108205-24-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000035/cris-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:17:05.323358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}